Acelyrin, Inc. (NASDAQ:SLRN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Acelyrin, Inc. (NASDAQ:SLRN) have received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $11.17.

Several analysts have issued reports on SLRN shares. Wells Fargo & Company raised their price objective on shares of Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 16th. HC Wainwright lowered Acelyrin from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $18.00 to $6.00 in a research note on Wednesday, August 14th. Morgan Stanley cut their price objective on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Monday, August 19th. Finally, Piper Sandler lowered their target price on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a research note on Wednesday, August 14th.

Hedge Funds Weigh In On Acelyrin

Hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. bought a new position in shares of Acelyrin in the 1st quarter worth $183,000. ProShare Advisors LLC boosted its holdings in shares of Acelyrin by 69.9% in the 1st quarter. ProShare Advisors LLC now owns 19,871 shares of the company’s stock valued at $134,000 after buying an additional 8,176 shares in the last quarter. Blair William & Co. IL purchased a new position in shares of Acelyrin in the 1st quarter worth approximately $936,000. Vanguard Group Inc. raised its stake in shares of Acelyrin by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 6,237,543 shares of the company’s stock worth $42,103,000 after acquiring an additional 81,633 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its position in Acelyrin by 118.0% during the first quarter. Ameritas Investment Partners Inc. now owns 7,243 shares of the company’s stock valued at $49,000 after acquiring an additional 3,921 shares during the last quarter. 87.31% of the stock is currently owned by institutional investors.

Acelyrin Stock Performance

NASDAQ:SLRN opened at $5.97 on Monday. The firm has a market capitalization of $591.19 million, a PE ratio of -2.51 and a beta of 2.33. The stock’s fifty day moving average is $5.07 and its 200 day moving average is $4.92. Acelyrin has a fifty-two week low of $3.36 and a fifty-two week high of $10.50.

Acelyrin (NASDAQ:SLRN) last announced its earnings results on Tuesday, August 13th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.08). During the same quarter last year, the firm earned ($0.56) EPS. Equities analysts forecast that Acelyrin will post -3.08 EPS for the current year.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.